Lv61
2269 积分 2021-12-14 加入
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
1个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
1个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
1个月前
已完结
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?
1个月前
已完结
Hodgkin lymphoma: great progress with room for improvement
1个月前
已完结
Personalizing adjuvant therapy for patients with colorectal cancer
1个月前
已完结
T-DXd plus pertuzumab effective as first-line therapy
1个月前
已完结
Vebreltinib effective in MET-amplified NSCLC
1个月前
已完结
Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours
1个月前
已完结
Two decades of PARP inhibitor synthetic lethality in cancer
1个月前
已完结
皖公网安备34019202002308
